OBJECTIVE： To observe clinical efficacy of bevacizumab or cetuxizumab combined with FOLFOX4 regimen in the treatment of advanced rectal cancer. METHODS： 114 patients with rectal cancer were randomly assigned to cetuxizumab group and bevacizumab group， with 57 cases in each group， among which one patient of bevacizumab group withdrew from therapy. Both groups received FOLFOX4 regimen： oxaliplatin 85 mg/m2+calcium folinate 200 mg/m2， ivgtt， 2 h， and 5-FU 400 mg/m2， ivgtt， last， 5-FU 600 mg/m2，ivgtt，22 h. Cetuxizumab group was additional given cetuxizumab 500 mg/m2； bevacizumab group was additionally given bevacizumab 5 mg/kg，ivgtt. A treatment course lasted for 2 weeks. Both groups received 4 courses of treatment， and then clinical efficacy， toxic reaction and progression-free survival （PFS） were evaluated. RESULTS： Objective remission rate （RR）， disease control rate （DCR） and median PFS of cetuxizumab group was 45.61％， 92.98％ and 10.0 months， those of bevacizumab group were 48.21％， 87.50％ and 11.0 months； there was no statistical significance between 2 groups （P＞0.05）. No significant differences were found in the incidence of ADR such as sensory neurotoxicity， aleucocytosis， thrombopenia， nausea and vomiting， diarrhea and erythra between 2 groups （P＞0.05）. CONCLUSIONS： Both bevacizumab or cetuxizumab combined with FOLFOX4 regimen have a similar effect on patients with advanced cancer， with low incidence of toxic reaction.